Strategic Focus RNA-based therapeutics for unmet needs in Stress Urinary Incontinence and solid tumors indicate license and collaboration potential with larger pharma seeking novel modalities and dual-targeted approaches.

Clinical Pathway IND readiness for VMB-100 signals near-term engagement opportunities with CROs, clinical development partners, and contract research organizations to accelerate trials and expand indications.

Leadership Signals New Chairman of the Board and seasoned executives with drug discovery to clinic experience strengthen credibility for partnerships, co-development, or strategic investments.

Financial Position Current funding at $28M with a pre-clinical stage footprint presents opportunities for strategic investment, milestone-driven deals, or milestone-based collaborations to advance platform and programs.

Market Readiness Pipeline focus on RNA therapeutics with a proprietary VERSagile platform positions Versameb to collaborate with partners seeking innovative modalities to address hard-to-treat diseases and expand into new therapeutic areas.